Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Net Income towards Common Stockholders (2023 - 2025)

Historic Net Income towards Common Stockholders for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to -$43.7 million.

  • CG Oncology's Net Income towards Common Stockholders fell 11420.24% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 9228.62%. This contributed to the annual value of -$88.0 million for FY2024, which is 2985.49% down from last year.
  • According to the latest figures from Q3 2025, CG Oncology's Net Income towards Common Stockholders is -$43.7 million, which was down 11420.24% from -$41.4 million recorded in Q2 2025.
  • CG Oncology's 5-year Net Income towards Common Stockholders high stood at -$12.4 million for Q1 2023, and its period low was -$43.7 million during Q3 2025.
  • For the 3-year period, CG Oncology's Net Income towards Common Stockholders averaged around -$25.0 million, with its median value being -$20.4 million (2024).
  • In the last 5 years, CG Oncology's Net Income towards Common Stockholders plummeted by 1650.68% in 2024 and then plummeted by 11914.08% in 2025.
  • Over the past 3 years, CG Oncology's Net Income towards Common Stockholders (Quarter) stood at -$22.5 million in 2023, then plummeted by 41.39% to -$31.8 million in 2024, then tumbled by 37.46% to -$43.7 million in 2025.
  • Its last three reported values are -$43.7 million in Q3 2025, -$41.4 million for Q2 2025, and -$34.5 million during Q1 2025.